

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Melanoma	Microphthalmia-associated transcription factor (MITF); TYRO3 protein tyrosine kinase (TYRO3)	<i>In vitro</i> studies suggest that inhibiting TYRO3 could help treat melanoma. In human melanoma cells, TYRO3 levels were higher than those in normal cells. <i>TYRO3</i> knockdown reduced cell proliferation, increased cell sensitivity to chemotherapeutics and decreased the potential of the cells to form tumors in mice. Next steps could include developing small molecule or antibody inhibitors of TYRO3 to treat melanoma.  <b>SciBX 2(37); doi:10.1038/scibx.2009.1402</b> <b>Published online Sept. 24, 2009</b>	Patented; unavailable for licensing	Zhu, S. <i>et al. Proc. Natl. Acad. Sci. USA</i> ; published online Sept. 21, 2009; doi:10.1073/pnas.0909292106 <b>Contact:</b> Xu Wu, Genomics Institute of the Novartis Research Foundation, San Diego, Calif. e-mail: <a href="mailto:xwu@gnf.org">xwu@gnf.org</a> <b>Contact:</b> Peter G. Schultz, The Scripps Research Institute, La Jolla, Calif. e-mail: <a href="mailto:schultz@scripps.edu">schultz@scripps.edu</a>